Can Oxytocin Help People Stop Drinking? A Review of the Evidence So Far

Narrative review of preclinical (animal) and clinical (human) studies on intranasal and systemic oxytocin for alcohol use disorders and heavy drinking. The review also discusses trial design frameworks and the parameters (dosing, timing, route of administration) that vary across studies and influence outcomes.

Alcohol use disorder affects an estimated 29.5 million Americans, yet only three medications are FDA-approved for its treatment — and all have limited effectiveness. Oxytocin represents a fundamentally different therapeutic approach: rather than directly blocking alcohol's effects, it targets the social bonding and stress-response systems that underlie addiction vulnerability. If effective, it could address the emotional and social drivers of alcohol dependence that current medications largely ignore.

The search for new alcohol use disorder treatments has increasingly focused on neuropeptides — natural brain chemicals that regulate stress, social behavior, and reward. Oxytocin joins GLP-1 agonists (which have also shown reduced alcohol interest in some patients) as a peptide-based approach to addiction. The convergence of multiple peptide systems with alcohol behavior suggests that addiction may fundamentally be a disorder of peptide signaling, opening a new pharmacological frontier beyond traditional medications like naltrexone and acamprosate.

This is a narrative review, not a systematic review or meta-analysis, so it does not quantitatively pool results. The existing evidence base is small, with inconsistent findings across studies. Dosing protocols, routes of administration, and outcome measures vary widely. Most human studies are small and short-term. The mechanisms by which oxytocin affects alcohol behavior are not fully understood.